TDR collaboration with the pharmaceutical industry

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 100, Issue SUPPL. 1, 2006, Pages

  Gutteridge, W E ^a  

^a NONE   (United Kingdom)

Author keywords

Drugs; Pharmaceutical industry; TDR; Tropical diseases

Indexed keywords

AMPHOTERICIN B; ARTEMETHER; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; ATOVAQUONE PLUS PROGUANIL; CHLORPROGUANIL PLUS DAPSONE; EFLORNITHINE; FANSIMEF; GATIFLOXACIN; HALOFANTRINE; IVERMECTIN; MEFLOQUINE; MILTEFOSINE; NEW DRUG; PAROMOMYCIN; PRAZIQUANTEL; STIBOGLUCONATE SODIUM;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CLINICAL TRIAL; COLOMBIA; DRUG APPROVAL; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; GERMANY; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; INDIA; MALARIA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCHOCERCIASIS; PATENT; REGISTER; REPRODUCTIVE TOXICITY; SCHISTOSOMIASIS; TERATOGENICITY; TREATMENT INDICATION; TROPICAL DISEASE; VISCERAL LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; DRUG EVALUATION; DRUG INDUSTRY; FEMALE; HUMANS; INTERPROFESSIONAL RELATIONS; LEISHMANIASIS; MALE; PHOSPHORYLCHOLINE; PUBLIC SECTOR; TROPICAL MEDICINE;

ASTA;

EID: 33749353207     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2006.02.013     Document Type: Article

References (11)

1. Berman J., Badaro R., Thakur C.P., Wasanna K.M., Behbehani K., Davidson R., Kuzoe F., Pang L., Weerasuriya K., and Bryceson A.D.M. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ 76 (1998) 25-32
2. Chunge C.N., Owate J., Pamba H.O., and Dunno L. Treatment of visceral leishmaniasis in Kenya with aminosidine alone or in combination with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 84 (1990) 221-225
3. Croft S.L., and Engel J. Miltefosine - discovery of the antileishmanial activity of phospholipids derivatives. Trans. R. Soc. Trop. Med. Hyg. 100 Suppl. 1 (2006)
4. Davidson R.N., Croft S.L., Scott A., Maini M., Moody A.H., and Bryceson A.D.M. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337 (1992) 1061-1062
5. Davidson R.N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G.B., Pempinello R., Scott S., Raimondi F., Cascio A., Prestileo T., Caldeira L., Wilkinson R.J., and Bryceson A.D.M. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. QJM 87 (1994) 75-81
6. Jha T.K., Olliaro P., Thakur C.P.N., Kanyok T.P., Singhania B.L., Singh I.J., Singh N.K.P., Akhoury S., and Jha S. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316 (1998) 1200-1205
7. Neal R.A., Allen S., McCoy N., Olliaro P., and Croft S.L. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35 (1995) 577-584
8. Seaman J., Pryce D., Sondorp H.E., Moody A., Bryceson A.D.M., and Davidson R.N. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 168 (1993) 715-720
9. Sinderman H., and Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100 Suppl. 1 (2006)
10. Sundar S., Jha T.K., Thakur C.P., Bhattacharya S.K., and Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100 Suppl. 1 (2006)
11. Thakur C.P., Bhowmick S., Dolfi L., and Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomised dose-finding clinical trial. Trans. R. Soc. Trop. Med. Hyg. 89 (1995) 219-223